FOLFOXIRI + Bevacizumab

Phase 3Monoclonal antibody

FOLFOXIRI + Bevacizumab is one of 28 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Vectibix

Amgen

Phase 3

45 2

Braftovi

Pfizer

Phase 3

11 3

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

2 4

Cosela

PPharmacosmos A/S

Phase 3

1 5

Fusilev

DDurata Therapeutics International BV (an Affiliate of Actavis, Inc.)

Phase 3

1 6

Vatalanib

Novartis

Phase 3

2 7

XL092

Roche

Phase 3

1 8

PF-08634404

Pfizer

Phase 3

—9

FOLFOX 2d

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 10

Brivanib Alaninate

GGynecologic Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Metastatic Colorectal Cancer

NCT07229846

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer3 trials

FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type

Unknown status·SSun Yat-sen University·Phase 2·NCT02350530·138 enrolled

Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells

Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 3·NCT01640405·350 enrolled

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

Not yet recruiting·YYanqiao Zhang·Phase 2·NCT07229846·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for FOLFOXIRI + Bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFOXIRI + Bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFOXIRI + Bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: SSun Yat-sen University

FOLFOXIRI + Bevacizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Metastatic Colorectal Cancer3 trials

References

Drug Info

Quick Facts

Related News